COMPOSITIONS AND METHODS FOR LOWERING TRIGLYCERIDES
In various embodiments, the present invention provides compositions and methods for treating and/or preventing cardiovascular-related diseases in subject in need thereof.
1 .- 8 . (canceled)
9 . A pharmaceutical composition comprising eicosa-5,8,11,14,17-pentaenoic acid (EPA) in a monoglyceride form, a diglyceride form, and/or a triglyceride form, wherein the EPA represents at least about 60%, by weight, of all fatty acids present in the pharmaceutical composition.
10 . The pharmaceutical composition of claim 9 , further comprising EPA in its free acid form.
11 . The pharmaceutical composition of claim 9 , further comprising no more than about 10% docosahexaenoic acid (DHA) or a derivative thereof.
12 . The pharmaceutical composition of claim 11 , wherein the derivative of DHA is ethyl-DHA (E-DHA).
13 . The pharmaceutical composition of claim 9 , wherein the EPA is present in the pharmaceutical composition in an amount of about 50 mg to about 5000 mg.
14 . The pharmaceutical composition of claim 9 , wherein the pharmaceutical composition is formulated to provide a subject with a daily dose of EPA of about 1 mg to about 10,000 mg.
15 . A pharmaceutical composition comprising eicosa-5,8,11,14,17-pentaenoic acid (EPA) in a monoglyceride form, a diglyceride form, and/or a triglyceride form, wherein the EPA is present in the pharmaceutical composition in an amount of about 50 mg to about 5000 mg.
16 . The pharmaceutical composition of claim 15 , further comprising EPA in its free acid form.
17 . The pharmaceutical composition of claim 14 , further comprising no more than about 10% docosahexaenoic acid (DHA) or a derivative thereof.
18 . The pharmaceutical composition of claim 16 , wherein the derivative of DHA is ethyl-DHA (E-DHA).
19 . The pharmaceutical composition of claim 15 , wherein the EPA represents at least about 60%, by weight, of all fatty acids present in the pharmaceutical composition.
20 . The pharmaceutical composition of claim 15 , wherein the pharmaceutical composition is formulated to provide a subject with a daily dose of EPA of about 1 mg to about 10,000 mg.
21 . A pharmaceutical composition comprising an ester form of EPA that is not EPA ethyl ester and wherein the EPA ester represents at least about 60%, by weight, of all fatty acids present in the pharmaceutical composition.
22 . The pharmaceutical composition of claim 21 , further comprising EPA in its free acid form.
23 . The pharmaceutical composition of claim 21 , further comprising no more than about 10% docosahexaenoic acid (DHA) or a derivative thereof.
24 . The pharmaceutical composition of claim 23 , wherein the derivative of DHA is ethyl-DHA (E-DHA).
25 . The pharmaceutical composition of claim 22 , wherein the EPA ester and/or EPA free acid is present in the pharmaceutical composition in an amount of about 50 mg to about 5000 mg.
26 . The pharmaceutical composition of claim 22 , wherein the pharmaceutical composition is formulated to provide a subject with a daily dose of EPA ester and/or EPA free acid of about 1 mg to about 10,000 mg.
27 . A pharmaceutical composition comprising an ester form of EPA that is not EPA ethyl ester and wherein the EPA ester is present in the pharmaceutical composition in an amount of about 50 mg to about 5000 mg.
28 . The pharmaceutical composition of claim 27 , further comprising EPA in its free acid form.
29 . The pharmaceutical composition of claim 27 , further comprising no more than about 10% docosahexaenoic acid (DHA) or a derivative thereof.
30 . The pharmaceutical composition of claim 29 , wherein the derivative of DHA is ethyl-DHA (E-DHA).
31 . The pharmaceutical composition of claim 28 , wherein the EPA ester and/or EPA free acid represents at least about 60%, by weight, of all fatty acids present in the pharmaceutical composition.
32 . The pharmaceutical composition of claim 28 , wherein the pharmaceutical composition is formulated to provide a subject with a daily dose of EPA ester and/or EPA free acid of about 1 mg to about 10,000 mg.